Effects on the endocrine system of long-term treatment with the luteinizing hormone—releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia

References

• Koutsilieris M, Tolis G. Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma. Prostate 1983; 4: 569–77
   PubMed Web of Science ®Google Scholar
• Sharifi R, Soloway M, The Leuprolide Study Group. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol 1990; 143: 68–71
   PubMed Web of Science ®Google Scholar
• Schroeder F H, Lock T MTW, Chadha D R, Debruyne F MJ, Karthaus H FM, de Jong F H, et al. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate. J Urol 1987; 137: 912–8
   PubMedGoogle Scholar
• Peters C A, Walsh P C. The effect of nafarelin acetate, a luteinizing-hormonre-leasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987; 317: 599–617
   PubMed Web of Science ®Google Scholar
• Gabrilove J L, Levine A C, Kirschenbaum A, Droller M. Effect of long-acting gonadotropin-releasing hormone analog (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy. J Clin Endocrinol Metab 1989; 69: 629–32
   PubMed Web of Science ®Google Scholar
• Matzkin H, Chen J, Lewysohn O, Braf Z. Treatment of benign prostatic hypertrophy by a long-acting gonadotropin-releasing hormone analogue: l-year experience. J Urol 1991; 145: 309–12
   PubMedGoogle Scholar
• Eri L M, Tveter K J. A prospective, placebo-controlled study of the luteinizing hormone—releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J Urol 1993; 150: 359–64
   PubMed Web of Science ®Google Scholar
• Mahler C, Verhelst J, Chaban M, Denis L. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone—releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue. Cancer 1991; 67: 557–9
   PubMed Web of Science ®Google Scholar
• Findling J W, Tyrrell J B. Anterior pituitary gland. Basic and clinical endocrinology, 3rd ed., F S Greenspan. Prentice Hall, Englewood Cliffs, New Jersey 1991; 79–132
   Google Scholar
• Bartsch W, Horst H-J, Becker H, Nehse G. Sex hormone binding globulin binding capacity, testosterone, 5 alpha-dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment. Acta Endocrinol (Copenh) 1977; 85: 650–64
   PubMedGoogle Scholar
• Røhl H F, Beuke H-P. Effect of orchidectomy on serum concentrations of testosterone and dihydro-testosterone in patients with prostatic cancer. Scand J Urol Nephrol 1992; 26: 11–14
   PubMed Web of Science ®Google Scholar
• Rizzo M, Mazzei T, Mini E, Periti P. Leuprorelin acetate depot in advanced prostatic cancer: a phase II muticentre trial. J Int Med Res 1990; 18(suppl 1)114–25
   PubMedGoogle Scholar
• O'Brien A, Hibberd M. Clinical efficacy and safety of a new leuprorelin acetate depot formulation in patients with advanced prostatic cancer. J Int Med Res 1990; 18(Suppl 1)57–68
   PubMedGoogle Scholar
• Giraud B. Interim report of a large French multi-centre study of efficacy and safety of 3.75 mg leuprorelin depot in metastatic prostatic cancer. J Int Med Res 1990; 18(Suppl 1)84–9
   PubMedGoogle Scholar
• Matzkin H, Kaver I, Lewysohn O, Ayalon D, Braf Z. The role of increased prolactin levels under GnRH analogue treatment in advanced prostatic carcinoma. Cancer 1988; 61: 2187–91
   PubMedGoogle Scholar
• Siegel Y I, Korczak D, Lindner A. Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate. Eur Urol 1991; 19: 16–8
   PubMedGoogle Scholar
• Nokin J, Vekemans M, L'Hennite M, Robyn C. Circadian periodicity of serum prolactin concentration in man. Br Med J 1972; 3: 561–2
   PubMed Web of Science ®Google Scholar
• Tyrrell J B, Aron D C, Forsham P H. Glucocorticoids and adrenal androgens. Basic and clinical endocrinology, 3rd ed., F S Greenspan. Prentice Hall, Englewood Cliffs, New Jersey 1991; 323–62
   Google Scholar
• Lukkarinen O, Hammond G L, Kontturi M, Vihko R. Long-term effects of endocrine treatment in advanced prostatic carcinoma patients. Invest Urol 1980; 17: 328–31
   PubMedGoogle Scholar
• Carlström K, Collste L, Eriksson A, Henríksson P, Pousette Å, Stege R, et al. A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomy. Prostate 1989; 14: 177–82
   PubMed Web of Science ®Google Scholar
• Lunglmayr G, Girsch E, Meixner E M, Viehberger G, Bieglmayer C. Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate. Urol Res 1988; 16: 315–19
   PubMedGoogle Scholar
• Braunstein D G. Testes. Basic and clinical endocrinology, 3rd ed., F S Greenspan. Prentice Hall, Englewood Cliffs, New Jersey 1991; 407–41
   Google Scholar